Want to see DNA full AI Analyst Report?
Top Page
Ginkgo Bioworks Holdings
(NYSE:DNA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$7.50
▼(-0.53% Downside)
Action:Reiterated
Date:08/20/26
DNA scores low-to-mid primarily due to weak financial performance—shrinking revenue, very large operating losses, and ongoing cash burn. The earnings call adds modest support from reaffirmed cash-burn guidance, strong liquidity, and improved long-term commitments, but near-term revenue declines and profitability headwinds persist. Technicals and valuation are both unsupportive, with the stock below major moving averages and losses limiting P/E-based valuation.
Positive Factors
High Gross Margin
The high gross margin indicates delivered platform and bioengineering services can have attractive unit economics. If Ginkgo restores program volume and scales fixed costs, this provides a foundation for improving contribution and eventual profitability.
Negative Factors
Severe Revenue Contraction
The sustained revenue decline shows that customer program volume and commercialization conversion remain weak. Lower scale makes Ginkgo’s substantial platform costs harder to absorb and delays the operating leverage needed to support a durable path to profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margin
The high gross margin indicates delivered platform and bioengineering services can have attractive unit economics. If Ginkgo restores program volume and scales fixed costs, this provides a foundation for improving contribution and eventual profitability.
Read all positive factors
Ginkgo Bioworks Holdings Key Performance Indicators (KPIs)
Any
Operating Income by Segment
Reveals profitability across different business units, highlighting which segments drive earnings and where there may be challenges or opportunities for growth.
Reveals profitability across different business units, highlighting which segments drive earnings and where there may be challenges or opportunities for growth.
Data provided by:
The Fly
The FlyGinkgo Bioworks Holdings (DNA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$486.87M
Dividend YieldN/A
Average Volume (3M)1.03M
Price to Earnings (P/E)―
Beta (1Y)3.14
Revenue Growth-51.54%
EPS Growth7.05%
CountryUS
Employees485
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.02
Shares Outstanding55,383,810
10 Day Avg. Volume808,738
30 Day Avg. Volume1,025,627
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)2.71
P/FCF Ratio-2.58
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside19.36% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)-3.46
Revenue Forecast (FY)$91.50M
Ginkgo Bioworks Holdings Business Overview & Revenue Model
Company Description
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and deve...
How the Company Makes Money
Ginkgo primarily generates revenue through two broad models: (1) platform (foundry) services and (2) downstream value participation. Platform services revenue comes from customer-funded programs where Ginkgo performs R&D work—such as organism/stra...
Ginkgo Bioworks Holdings Earnings Call Summary
Earnings Call Date:Aug 05, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Neutral
The call balanced significant strategic and operational progress with near-term financial headwinds. Positives include major academic and national lab contracts, rapid expansion and scale demonstration of Nebula, a competitive ADME product with strong price/performance and a solid cash position plus a reduced long‑term Google Cloud commitment. Negatives include steep year‑over‑year revenue declines, wider GAAP losses and worse adjusted EBITDA in Q2, elevated quarter‑specific cash burn and ongoing excess lease costs. Management emphasizes cost discipline, a shift toward investing in autonomous labs and predictable cash burn guidance for 2026, but revenue recognition timing for automation deals and the need to further mature operations create near‑term uncertainty.Positive Updates
Strategic NSF and Academic Wins
Selected to build autonomous labs for MIT, Caltech, University of Maryland and Northwestern (NSF-funded or separate grant for MIT), positioning Ginkgo as a supplier of campus cloud/autonomous labs and training the next generation of scientists.
Negative Updates
Sharp Revenue Decline
Q2 2026 revenue was $20M, down 48% YoY; revenue for the first 6 months of 2026 was $40M, down 49% YoY (or ~42% decline excluding $7.5M noncash revenue in H1 2025 related to BiomEdit).
Read all updates
Q2-2026 Updates
Positive
Negative
Strategic NSF and Academic Wins
Selected to build autonomous labs for MIT, Caltech, University of Maryland and Northwestern (NSF-funded or separate grant for MIT), positioning Ginkgo as a supplier of campus cloud/autonomous labs and training the next generation of scientists.
Read all positive updates
Company Guidance
Management reaffirmed full‑year 2026 cash‑burn guidance of $125 million to $150 million while saying they expect further cash‑burn improvement in H2; the company enters H2 with $302 million of cash and cash equivalents plus $87 million of restricted cash. Key Q2 and H1 metrics cited: Q2 revenue $20 million (down 48% YoY) and H1 revenue $40 million (down 49% YoY; ~42% decline ex. $7.5 million non‑cash BiomEdit item), R&D $30 million in Q2 (down 4% YoY), G&A $12 million in Q2 (down 26% YoY), net loss from continuing operations of $57 million in Q2 (vs $53 million prior year), and adjusted EBITDA of negative $36 million in Q2 (vs negative $25 million), which includes $14 million of excess‑lease carrying costs (up from $12 million). Cash‑burn was $45 million in Q2 and $93 million in the first half (down 3% from $96 million), noting a $17 million ATM raise (excluded from cash‑burn) and a $14 million Google Cloud payment in Q1 that raised near‑term burn; the Google Cloud reset reduced future minimum commitments by more than $100 million and extended the term from 3 to 6 years.Ginkgo Bioworks Holdings Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
46
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 111.86M | 170.16M | 227.04M | 251.46M | 477.71M | 313.84M |
| Gross Profit | 89.59M | 138.63M | 188.49M | 197.45M | 273.49M | 184.15M |
| EBITDA | -209.15M | -254.61M | -484.39M | -821.29M | -2.06B | -1.81B |
| Net Income | -290.80M | -312.76M | -547.03M | -892.87M | -2.10B | -1.83B |
Balance Sheet | ||||||
| Total Assets | 990.05M | 1.12B | 1.38B | 1.67B | 2.54B | 2.07B |
| Cash, Cash Equivalents and Short-Term Investments | 302.16M | 422.62M | 561.57M | 944.07M | 1.32B | 1.55B |
| Total Debt | 404.11M | 439.88M | 467.73M | 239.31M | 442.59M | 23.03M |
| Total Liabilities | 569.76M | 611.11M | 661.39M | 568.19M | 803.04M | 503.61M |
| Stockholders Equity | 420.28M | 508.59M | 716.06M | 1.10B | 1.74B | 1.51B |
Cash Flow | ||||||
| Free Cash Flow | -190.12M | -178.72M | -382.13M | -336.30M | -304.47M | -310.34M |
| Operating Cash Flow | -170.24M | -171.06M | -319.58M | -295.50M | -252.20M | -253.82M |
| Investing Cash Flow | 56.50M | -240.29M | -62.24M | -80.69M | -67.39M | -73.26M |
| Financing Cash Flow | 34.55M | 17.77M | -1.74M | -3.22M | 95.34M | 1.53B |
Ginkgo Bioworks Holdings Technical Analysis
Negative
7.54
Price Trends
8.38
Negative
8.32
Negative
8.35
Negative
Market Momentum
-0.32
Negative
46.27
Neutral
68.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DNA, the sentiment is Negative. The current price of 7.54 is below the 20-day moving average (MA) of 7.65, below the 50-day MA of 8.38, and below the 200-day MA of 8.35, indicating a bearish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 46.27 is Neutral, neither overbought nor oversold. The STOCH value of 68.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DNA.
Ginkgo Bioworks Holdings Risk Analysis
Ginkgo Bioworks Holdings disclosed 69 risk factors in its most recent earnings report. Ginkgo Bioworks Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ginkgo Bioworks Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $261.12M | 16.53 | 20.50% | ― | 10.99% | -12.12% | |
59 Neutral | $1.58B | -11.78 | -59.21% | ― | -62.28% | 15.36% | |
56 Neutral | $763.31M | -48.69 | -13.08% | ― | ― | 29.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.36B | -7.74 | -49.11% | ― | ― | 91.41% | |
46 Neutral | $486.87M | -1.45 | -60.21% | ― | -51.54% | 7.05% | |
43 Neutral | $362.68M | -0.91 | -91.62% | ― | -55.00% | 51.58% |
* Healthcare Sector Average
DNA
Ginkgo Bioworks Holdings
6.96
-5.71
-45.07%
NAGE
Niagen Bioscience
3.29
-6.61
-66.77%
MNPR
Monopar Therapeutics Inc
111.89
77.74
227.64%
LYEL
Lyell Immunopharma
14.53
3.45
31.14%
JBIO
Jade Biosciences
20.84
12.94
163.80%
ABSI
AbSci
8.71
6.32
264.44%
Ginkgo Bioworks Holdings Corporate Events
Business Operations and StrategyFinancial Disclosures
Ginkgo Bioworks to Review Q2 2026 Performance
Neutral
Jul 30, 2026
Ginkgo Bioworks Holdings, Inc., a synthetic biology tools provider offering autonomous, robotics-powered labs and cloud-based contract research services, focuses on making biological engineering more accessible and productive for scientists and co...
Executive/Board ChangesShareholder Meetings
Ginkgo Bioworks Shareholders Back Board, Governance Structure
Positive
Jun 12, 2026
On June 11, 2026, Ginkgo Bioworks Holdings, Inc. held its 2026 annual meeting of shareholders, with approximately 77.15% of the combined Class A and Class B shares and 93.77% of Class B shares represented. Shareholders confirmed the company’...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.